Table 1 Characteristics of the study sample

 Breast cancer^a, N (%)

90 (62.5)

 Ovarian cancer, N (%)

5 (3.5)

 Both breast and ovarian, N (%)

1 (0.7)

 Both breast and endometrial, N (%)

1 (0.7)

 Unaffected, N (%)

47 (32.6)

Time since cancer diagnosis, mean (SD)

10.9 (7.9)

Years since testing, mean (SD)

5.2 (1.2)

Age at F/U, mean (SD)

49.6 y (10.0)

Range

32y-76y

College degree or higher, N (%)

139 (96.5)

Jewish, N (%)

48 (33.3)

White, N (%)

135 (93.8)

Married, N (%)

111 (77.1)

Relatives with cancer, mean (SD)

 Breast cancer

2.3 (1.2)

 Ovarian cancer

0.5 (0.7)

 Breast or ovarian cancer

2.8 (1.5)

Oophorectomy

 Risk reducing oophorectomy^b N (%)

94 (65.2)

 Prior to genetic testing, N (%)

29 (20.1)

 After genetic testing, N (%)

65 (45.1)

 For treatment of ovarian cancer, N (%)

6 (4.2)

 Other^c, N (%)

10 (6.9)

 Ovaries intact, N (%)

34 (23.6)

Years since risk reducing oophorectomy, mean (SD)

5.49 (4.18)

Mastectomy

 Risk reducing mastectomy^d,e, N (%)

64 (44.4)

 Prior to genetic testing, N (%)

24 (16.6)

 After genetic testing, N (%)

40 (27.8)

 Bilateral for treatment, N (%)

13 (9.0)

 Unilateral for treatment, N (%)

12 (8.3)

 Both breasts intact, N (%)

55 (38.2)

Years since risk reducing mastectomy, mean (SD)

6.35 (6.3)

Satisfaction with management decisions, mean (SD)

23.4 (2.87)

Very satisfied with management decisions, % (number)

65.3% (94/144)

Satisfaction with genetic testing decision, mean (SD)

23.6 (2.56)

Very satisfied with genetic testing decisions, % (number)

66.0% (93/141)

Quality of life, FACT-B for affected women, mean (SD)

117.0 (19.0)

Quality of life, SF-12 for unaffected women, mean (SD)

100.8 (14.0)